InvestorWire NewsRoom


Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)
September 17, 2021

Differentiated Approach in Psychedelics Boosts Confidence in Upcoming Clinical Trials for Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

  • Pharmaceutical company Tryp Therapeutics is pursuing novel solutions to medical conditions with unmet needs, working to establish the efficacy and safety of the company’s trademarked synthetic psychedelic drug candidate
  • The company’s products — TRP-8802 and TRP-8803 — aim to provide new therapies for select eating disorders with specific neurological causes, as well as pain and addition concerns
  • Tryp is preparing Phase 2a and Phase 2b clinical trials and expects to advance its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) platform in conjunction with research teams at the University of Florida and the University of Michigan
  • The DEA recently recommended a significant increase in cannabis and psilocybin use in medical science research, and the White House has asked Congress to consider changing drug legislation to better address the use of those drugs in clinical research

Two years after the U.S. Food and Drug Administration (“FDA”) declared the hallucinogenic substance psilocybin a “breakthrough therapy” to speed the process of the drug’s scientific clinical trials and reviews (, Michigan continues to cement its reputation as a hotbed for medicinal psychedelics advocacy and research, and proponents there believe society has reached a watershed moment for the substances’ acceptance.

Law enforcement officials in the state’s Ann Arbor region have effectively decriminalized natural compounds with hallucinogenic properties deemed illegal under state and federal law (although not synthetic compounds such as LSD), and last month Ann Arbor’s City Council voted 10-0 to declare September “Entheogenic Plant and Fungi Awareness Month.” As a result, the city will celebrate a “sacred plant and mushroom festival” called Entheo Fest every September, beginning Sept. 19 ( 

The decisions highlight a growing cultural shift not unlike the transformation of cannabis’ stigma to a general acceptance of marijuana’s potential for therapeutic and recreational use when produced under quality constraints by recognized business enterprises in recent years. 

Earlier this month, the Drug Enforcement Administration (“DEA”) proposed a huge increase in the production of marijuana and psilocybin for research purposes with the hope of accelerating new federally approved therapeutic medications ( The White House then issued a set of recommendations to Congress asking lawmakers to consider addressing addiction worries and proposals for new clinical research involving marijuana and psychedelics by changing the way select hallucinogenic substances are regulated ( 

San Diego-based Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on novel bioscience solutions for medical conditions with unmet needs, specifically oriented toward developing its synthetic psilocybin candidates through clinical trials that target chronic pain and select eating disorders. 

The company expects to soon launch a Phase 2a clinical trial to determine the efficacy of its psychedelic drug candidate TRP-8802 in treating Prader-Willi Syndrome (“PWS”), hypothalamic obesity eating disorder resulting from the removal of a brain tumor, and binge eating disorder. TRP-8802 will be used in combination with psychotherapy under professional care. 

“Ultimately, of course, we hope it will help people with overall eating disorders, but first we’re going to focus on people with specific neurologic causes of those eating disorders,” Dr. Jennifer Miller, the trial’s principal investigator, stated during an interview with The Dales Report in May ( 

“Psychotherapy is an integral part of Tryp’s novel treatment methods to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect,” the company added in a news release last month ( “Participants will undergo preparatory psychotherapy sessions with trained therapists leading to two dosing sessions in the upcoming Phase 2a clinical trial for eating disorders”.

Tryp Therapeutics then plans to proceed into Phase 2b clinical trials with drug candidate TRP-8803 to test the trademarked product’s ability to penetrate the natural blood-brain barrier and effectively respond to pain and addiction concerns. 

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent Articles

Release Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).